[Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results].
OBJECTIVE
To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA).


METHODS
Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of which was inadequate for these patients. Remicade was infused intravenously in a dose 200 mg 4 times for 22 weeks.


RESULTS
Remicade produced positive clinical and laboratory effects as early as the first infusion. The response was observed during 22 weeks of the treatment in 17 of 25 patients. Remicade tolerance was good. One patient failed the treatment because of development of collapse.


CONCLUSIONS
Pilot results of remicade trial point to its high therapeutic potential and perspectives in rheumatology.
Lukina
G V
GV
Sigidin
Ia A
IaA
Chichasova
N V
NV
Balabanova
R M
RM
Belenkiĭ
A G
AG
Imametdinova
G R
GR
Barskova
V G
VG
Bochkova
A G
AG
Gukasian
D A
DA
Egorova
O N
ON
Karateev
D E
DE
Kolosova
I R
IR
Loginova
E Iu
EIu
Pudovkina
E Iu
EIu
Stanislav
M L
ML
Taukumova
L A
LA
Fedina
T P
TP
Nasonov
E L
EL
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D000069285:Infliximab; D007262:Infusions, Intravenous; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D010865:Pilot Projects; D013997:Time Factors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate